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Thyroid hormones are known to affect skeletal growth and maturation by influencing both bone resorption and bone formation. Their exact 
mechanism of action, however, is still unknown. Local factors such as prostaglandins, TGF-/I or IGF-I were suggested to mediate their effects. Thyroid 
hormones were reported to stimulate expression of IGF-I mRNA in liver and kidney and to increase IGF-I release from bone organ cultures and 
osteoblast-like cells. Therefore we studied the effect of thyroid hormones on IGF-I mRNA expression in MC3T3-El cells. The cells were grown in 
culture for 5 to 7 days and treated with triiodothyronine (1O-“-1O-6 M) and thyroxin (10e6 M) for l-24 h. Cellular mRNA was isolated and subjected 
to Northern hybridization. The amount of IGF-I mRNA, which is already expressed in this cell line under control conditions, was markedly enhanced 
by T3 and T4. This effect was found to be dose-dependent with a maximum at lo-‘M and could already be seen after 3 h increasing up to 24 h. Our 
findings indicate that IGF-I expression in osteoblasts is directly regulated by thyroid hormones. We conclude that IGF-I expression belongs to the 
phenotypic characteristics of mature osteoblasts, and that thyroid hormones play an important role in differentiation of MC3T3-El cells along the 
osteoblastic lineage. 
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1. Introduction 
Thyroid hormones are essential for normal growth 
and development in children and affect bone remodelling 
in adults. In vivo and in vitro data indicate that they 
influence both bone formation as well as bone resorp- 
tion. Hyperthyroidism and hypothyroidism are accom- 
panied by disturbances of bone and calcium metabolism 
[l]. Thyroidectomy in experimental animals resulted in 
delayed growth and skeletal maturation which effect was 
reversed by thyroxin (T4) treatment [2]. 
Based on in vitro data a direct effect of T4 and triiodo- 
L-thyronine (T3) on bone cells was postulated in previous 
investigations. Direct stimulation of bone resorption was 
observed in cultures of fetal rat limb bones [3,4] and of 
neonatal mouse calvaria [5-71. This is supported by the 
finding of specific thyroid hormone receptors in isolated 
nuclei from neonatal mouse calvaria [8], MC3T3-El cells 
[9] and in rat osteosarcoma cells [lO,l 11. 
Although direct influence of thyroid hormones on 
bone cell functions was clearly established, their exists 
some evidence that their effects on bone remodelling are 
mediated by local factors produced by the bone cells. 
Thus prostaglandins [7] and TGF-/I [ 121 seem to mediate 
partially the effect on bone resorption. On the other hand 
some investigators suggested IGF-I as a likely candidate 
to mediate their effect on bone formation [ 13,141. Indeed, 
IGF-I, one of the most prevalent growth factors synthe- 
sized by bone cells and present in bone, is known to be 
regulated by systemic hormones such as parathyroid 
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hormone [15-l 71 and estrogens [ 181 as well as local fac- 
tors such as prostaglandin E2 [ 191. 
More recently it was shown that thyroid hormones 
and growth hormone interact to regulate IGF-I mRNA 
and circulating levels in the rat and that thyroid 
hormones induce IGF-I expression in liver and kidney 
cells at the mRNA and protein level [20]. Based on these 
observations we were interested whether thyroid 
hormones could influence IGF-I synthesis in bone cells 
at the mRNA level. We used MC3T3-El cells since pre- 
vious investigations showed that this osteoblastic cell line 
has the capacity to synthesize IGF-I under basal and 
hormone stimulated culture conditions [21,22]. We now 
show that both T4 and T3 increase IGF-I mRNA levels 
in MC3T3-El cells. Since this work had been initiated it 
was reported that T3 stimulates IGF-I and IGF-I bind- 
ing protein-2 production by rat osteoblasts in vitro [23] 
as well as IGF-I content in the medium of rat bone tissue 
~241. 
2. Materials and methods 
2.1. Cell culture 
MC3T3-El cells were kindly donated by Dr. Kumegawa (Meikai 
University, Department of Oral Anatomy, Sakado, Saitama 35002, 
Japan). The cells were cultured in Dulbecco’s mod&d Eagle’s medium 
(DMEM, Gibco Laboratories, Grand Island, NY) with 4.5 g/l glucose, 
supplemented with 5% or 10% fetal calf serum (FCS, Boehringer 
Mannheim, Germany) 30 &ml Gentamycin (Sigma, Germany) at 
37°C under 5% CO1 in humidified air. They were subcultured twice a 
week using 0.001% pronase E and 0.02% EDTA in Car’ and MgZ’ free 
phosphate-buffered saline (PBS). For experiments MC3T3-El cells 
were plated at a density of 2 x 105cells/cmz. The stimulation experi- 
ments were performed 5 to 7 days after seeding at about 80% conflu- 
ency. For treatment the medium was removed and the cell layer was 
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washed with PBS. After preincubation in DMEM supplemented with 
2% horse serum (cut-off MW 1000, heat-inactivated at 56“C, Sigma, 
Germany) for 1 h, the cells were incubated for 24 h in the same medium 
with or without T4 (10e6 M) and T3 (10-“-10-6 M) for the induction 
experiments. The dialysed horse serum was used to be sure to have no 
unspecific effects caused by low molecular weight factors present in the 
serum supplement. For the time course experiments culture was 
stopped at the respective time points. 
2.2. RNA-isolation and Northern hybridization 
Cytoplasmic RNA was isolated using the mini-prep method of M. 
Wilkinson [25] and the total amount of RNA was estimated by measur- 
ing the absorption at 260 mn with a Hitachi spectrophotometer. North- 
ern hybridization was performed by fractionating 1Opg total RNA on 
a 1% agarose gel containing 2.2 M formaldehyde according to Maniatis 
et al. [26]. After electrophoresis the gel was soaked in 50 mM NaOH 
for about 20 min and transferred to a nylon filter (NEN, Brussels) with 
2OxSSC (1 xSSC is 0.15 M NaCl and 0.015 M Na-citrate). After 
baking the filter for 2 h at 8O”C, hybridization was done for about 
l&16 h in 10% Dextransulfate, 1 M NaCl and 1% sodium-dodecylsul- 
fate after 10 min pre-hybridization in the same solution. For estimation 
of the amount of mRNA, the filters were exposed for 6 to 10 days and 
the autoradiograms were digitised and loaded into the NIH-Image 
program (Wayne Rasband, NIH). The density was estimated using the 
gel blotting macro. The hybridization probe was generated by 
ampliticati& of reverse t&scribed RNA with both primers 
TCTTCACATCTCTTCTACCTGG (5’ mimer) and GGTCTTGTT- 
TCCTGCACTTCC (3’ primer). The‘ Aplified’ fragment was cloned 
into the SmaI site of the SK- bluescript Phagemid (Stratagene, La Jolla, 
CA). The cloned IGF-I cDNA fragment was verified by sequencing. As 
a control we hybridized the same Northern blots using the XhoII to BglI 
fragment of rat GAPDH kindly provided by Dr. Busslinger (Research 
Institute of Molecular Pathology, Wenna). Probe labelling was per- 
formed either by transcription with [“*P]UTP using the phage promoter 
T3 or T7 according to the suppliers suggestions or with PCR [271 using 
the described PCR-primer. 
3. Results 
Fig. la shows the Northern blot of RNA isolated from 
untreated and thyroid hormone-treated (10e7 M T3 or 
10e6 M T4) cells. Both mRNAs for IGF-I [28] are detect- 
able in our cell line but are expressed in different 
amounts. Compared to controls an about 3-fold increase 
of IGF-I mRNA was found after treatment with 10e7 M 
T3 or 10m6 M T4 for 24 h. Concerning the two types of 
IGF-I mRNAs no difference in enhancement was detect- 
able. Fig. lb shows the hybridization of the same filter 
with the GAPDH probe for control of loaded RNA. The 
experiment was repeated four times with similar results 
concerning the stimulatory effect of T3 and T4 although 
the control levels of IGF-I mRNA showed interexperi- 
mental variance. We assume that the IGF-I mRNA lev- 
els in untreated MC3T3-El cells depend on the differen- 
tiation state of the cell line as we observed a constant rise 
of IGF-I rnRNA during prolonged incubation time of 
the cells (see also time course experiments in Fig. 3). 
As we could not find any significant differences be- 
tween the effects of T4 and T3 we used only T3 for 
further experiments. Fig. 2a shows the dose-response 
curve of T3 (10-6-10-11 M) on IGF-I mRNA expression. 
In these experiments the increase of IGF-I mRNA levels 
at the highest concentration (10Y6 M T3) was about 
Fig. 1 b - 
Fig. 1. (a) Expression of IGF-I mRNA in untreated (Co), T3 (lo-’ M) 
and T4 (10e6 M) treated MC3T3-El cells (treatment time: 24 h). Total 
RNA (1Opg) was analyzed by Northern blotting using the IGF-I probe. 
Both IGF-I mRNAs are detectable. Arrows indicate the position of the 
markers (16 S/23 S rRNA, E. cog. (b) Control hybridization of the blot 
shown in a with the GAPDH probe to show the amount of loaded 
mRNA. 
4-fold. The dose-response relationship found in our ex- 
periments is comparable to results from the literature 
concerning the effects of T3 on alkaline phosphatase 
activity in these cells [lo]. 
To get a further insight into the mechanism of the 
stimulatory effect of T3 on IGF-I expression, time course 
experiments (1,3,6 and 24 h) were performed. As shown 
in Fig. 3a there was no increase of IGF-I mRNA levels 
found after 1 h. Already 3 h after start of the incubation 
a stimulatory effect of T3 could be detected with an 
increase at 24 h. It also can be seen that the control levels 
of IGF-I mRNA in untreated cells shows a constant rise 
with prolonged incubation time which might reflect 
growth and differentiation of these cells during culture. 
Nevertheless at 3,6 and 24 h a distinct stimulatory effect 
of T3 was measured which reached an extent of about 
twice to threefold at 24 h. 
4. Discussion 
The result of our study show for the first time that 
thyroid hormones have the capacity to enhance IGF-I 
mRNA levels in the osteoblastic cell line MC3T3-El. 
This stimulatory effect was dose-dependent with a maxi- 
mum between 10m7 M and lO-‘j M T3 which is in good 
agreement with data concerning other biological effects 
of thyroid hormones in bone organ cultures or osteoblas- 
tic cells such as alkaline phosphatase activity [9]. Our 
finding is also consistent with recent studies which report 
an increase in medium IGF-I in response to thyroid 
hormones in cultures of fetal rat tibiae [29], UMR-106 
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cells and in fetal rat limb bones [24]. Significantly in- 
creased IGF-I levels were reported in the media of 
UMR-106 cells by the second day of culture with no 
further increase up to five days [23]. However, the in- 
crease of the message in MC3T3-El cells occurs already 
during the first 24 h. 
Interestingly, T3 has not only the capacity to stimulate 
IGF-I expression, synthesis and secretion in osteoblastic 
cells but could also stimulate the expression of IGF-I 
receptor mRNA as reported for chondrocytes [30]. This 
could indicate that at the level of the basic multicellular 
units (BMUs) under the influence of thyroid hormones 
certain cell types produce local growth factors while oth- 
ers express the respective receptors. 
In our earlier study we found that locally produced 
prostaglandins could act as mediators of the effects on 
bone formation and resorption [7]. Prostaglandin E2 is 
known to be a strong stimulator of IGF-I synthesis in 
osteoblastic cells [ 191 therefore we also tested whether the 
effect of T3 on IGF-I expression could be influenced by 
indomethacin. The lack of inhibitory influence of the 
cyclooxygenase inhibitor (data not shown) indicates that 
the effect of T3 on IGF-I expression is not mediated by 
prostaglandins. Thus prostaglandins and IGF-I inde- 
pendently could cooperate in mediating the anabolic ef- 
fects of thyroid hormones on bone as it is also discussed 
for parathyroid hormone [3 1,321. 
Studies with isolated osteoblasts and cocultures of os- 
teoblasts and osteoclasts indicated that osteoblasts are 
the primary site of action for thyroid hormones [33,34]. 
Indeed specific receptors are present on osteoblastic cells 
[8-111 and thyroid hormones are believed to exert their 
effects on bone cells through these nuclear receptors. In 
addition, putative plasma membrane binding sites for 
thyroid hormones in bone tissue mediating direct non 
genomic stimulation of the inositol phosphate second 
messenger system were postulated [35]. From our exper- 
iments we believe that neither a direct action of the thy- 
roid hormone/receptor complex on the IGF-I gene nor 
the stimulation of second messenger pathways can ex- 
plain the observed increase in IGF-I message. We con- 
clude this from the time course experiments which show 
a delayed effect (after 3 h) and from experiments with 
cycloheximid which itself stimulates IGF-I expression 
co 10-a lo-’ 10-n 10-9 10-10 10-11 
Fig. 2. (a) Dose-dependent IGF-I mRNA expression in T3 (10-1’-10-6 
M) treated MC3T3-El cells (Co, no treatment; treatment time, 24 h). 
1Opg RNA were analyzed by Northern blotting. (b) Control hybridiza- 
tion of the blot shown in a with the GAPDH probe. 
lh 3h 6h i4h 
Co T3 Co T3 Co T3 Co T3 
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Fig. 3a 
Fig. 3b 
Fig. 3. (a) Time course of the IGF-I mRNA expression in untreated 
(Co) and T3 (lo-’ M) treated MC3T3-El cells. 10 pg RNA were ana- 
lyzed by Northern blotting. (b) Control hybridization of the blot shown 
in a with the GAPDH probe. 
and does not alter the effect of T3 (data not shown). The 
latter result could be explained by the existence of a 
regulated repressor protein [36]. 
MC3T3-El cells in prolonged cultures are known to 
differentiate from a preosteoblastic phenotype to mature 
osteoblasts [37]. T3 treatment accelerates this differentia- 
tion, shown by stop of proliferation and increase of dif- 
ferentiated functions such as alkaline phosphatase activ- 
ity [9] and prostaglandin synthesis [38]. We speculate 
that the observed increase in IGF-I expression is also a 
consequence of accelerated osteoblastic differentiation 
of MC3T3-El cells after T3 treatment. The primary ef- 
fect of thyroid hormones on bone cells therefore could 
be stimulation of osteoblastic differentiation. IGF-I ex- 
pression and synthesis, consequently, belong to the im- 
portant phenotypic characteristics of mature osteoblasts 
which lay down and calcify the bone matrix. 
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